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A newly raised antiserum against the C-terminal region ofneuroendocrine protein 782 was used to purify a novel peptide from the culture media 
of the mouse corticotroph cell line AtT-20. Based on partial sequencing. this peptidc, which we call Cter-7B2, begins at Ser”‘and appears to result 
from the clcavagc of pro7B2 aftcl- a five-basic-residue sequcncc. Thus, 782 processing may contribute to the diversity of peptides found in neuronal 
and endocrine cells. 
7H2; Precursor protein; Antibody; Protcolytic processing: AtT-20 cell 
1. INTRODUCTION 
Most regulatory peptidcs (hormones, growth factors, 
neuromodulators) derive from specific proteolysis of 
large precursor proteins, most often at pairs of basic 
amino acids [I]. 7B2, a highly conserved marker of the 
secretory granules of neuronal and endocrine cells, 
carries such potential sites at its carboxyl portion [2-51. 
It could thus represent a substrate for proprotein con- 
vertases. In this study, we describe an antibody raised 
against the carboxyl end of 7B2 which has allowed us 
to purify and characterize a novel peptide derived from 
7B2 processing. 
2. MATERIALS AND METHODS 
2.1. Production of’uniiscra against [he curboxyl terminus of‘ 782 
The DNA sequence ncoding mouse 7B2,56_,86 was amplified by the 
polymerase chain reaction (PCR) from the cloned cDNA [2]. The 
O.l-kb PCR product was digested with EcuRI and BumHI and ligated 
into the plasmid pGEX-2T (Pharmacia) 161 cut with same enzymes, 
downstream of the gene encoding the S~/~lisroso,nnju~,onicum glutathi- 
one S-transferase (GST), in a continuous reading frame with it, under 
the control of the inducible Tut promoter. Esc&richiu co/i DH5a were 
transformed with the recombinant plasmid; plasmid was extracted 
from several clones and the inserted DNAs were sequenced to select 
those without PCR-caused missense or nonsense mutations. The 
production of fusion protein (GST--Cter-7B2) was induced with iso- 
propyl-@hiogalactopyranoside (IPTG) in a 2-liter culture of one such 
clone. The protein was purified by affinity chromatography on Gluta- 
thione-Sepharose 4B (Pharmacia) [6] and was used to immunize 
rabbits. 
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2.2. Radioitnmunoassa~v und inzmunoprecipiiution 
Radioimmunoassays (RIA) were performed as previously described 
for the N-terminal region of 782 [7]. For a standard assay, the C7B2 
antiserum was diluted 1:600 (final dilution). The tracer, a synthetic 
peptide 7B2,5, ,,, was ‘2JI-labelled by the chloramine T method (spec. 
act. 6~10~ cpming) and was used at 3~10~ cpm per tube. 
For immunoprecipitation, the samples werediluted I:1 with a buffer 
containing 2% Nonidet-P40,0.2% SDS, 1% sodium deoxycholate, 0.3 
M NaCI, 0. I M Tris-HCI, pH 8.0 (2x IP buffer). The antiserum (20 
~1) was added and the mixture was incubated at 4°C for 16 h, after 
which 50 11 of a 10% suspension of a fixed cell preparation of St&y- 
1ococcu.s aweus membranes (IgGSorb, The Enzyme Center) were 
added. After 30 min at 2l”C, the suspended material was sedimented 
at 6000 x g and 4°C for IO min, and the pellet was rinsed twice with 
Ix IP buffer. 
2.3. Purijication und sequencing of Cter-7B2 peptide 
As source for the peptide, we used AtT-20 cells infected with the 
recombinant vaccinia virus VV:m7B2 (to be described elsewhere) and 
expressing high levels of mouse 7B2. We followed the protocol of 
Hruby et al. [8] for production of the virus and for its use as expression 
vector to study prohormone processing in AtT-20 cells. Infected cells 
(4 x IO’ I.5 x 10’) were grown in 5-10 ml of Dulbecco Minimal 
Essential Medium (DMEM) containing 0.5% fetal bovine serum for 
I6 h. Media were collected and supplemented with phenylmethyl sul- 
fonyl fluoride (PMSF), iodoacetamide (IAA) and EDTA to final con- 
centrations of 1 mM, I mM and 2.5 mM, respectively. Cells were 
harvested in 500~1 of 0. I M Tris-HCI, pH 7.4, containing PMSF, IAA 
and EDTA as above, and were disrupted with 2 cycles of freezing and 
thawing followed by two 30-s sonication bursts on ice. The extracts 
were centrifuged at I4 000 x g for I5 min, and the supernatants 
collected. Media and cell extracts were acidified with trifluoroacetic 
acid (TFA) at 0.1%. They were fractionated by high performance 
liquid chromatography (HPLC) on a Vydac C-18 column (0.78 x 30 
cm) using 0.1% TFA for IO min, then a O-60% linear gradient of 
acetonitrile in 0.1% TFA. The fractions were analysed by RIA. 
In some experiments, incubation of VV:m7B2-infected cells was 
done in the presence of [“‘Slmethionine, [‘Hlphenylalanine, [‘HJleucine 
or [‘Hlvaline. The culture medium was subjected to immunoprecipita- 
tion as described above, and the radioactive precipitates were se- 
quenced on a gas-phase sequenator (Applied Biosystem, model 470A 
[91. 
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Fig. 1. (A) Plasmid pGEX-2T/Cter-7B2 construct. The inserted DNA sequence and the polypeptide it encodes are printed in bold. The PCR primer 
segment is underlined. The thrombin cleavage site to release the C-terminal peptide is shown. (B) IPTG induction of GST-Cter-7B2. Proteins 
extracted from 1 ml bacterial culture grown with or without 0.4 mM IPTG were resolved on a 0.1% SDS-15% PAGE and stained with Coomassie 
brilliant blue [16]. (C) Purification of GST-Cter-7B2 by chromatography on Glutathione-Sepharose 4B. Aliquots were analysed by SDS-PAGE 
as in (B). A two-liter culture yielded 16 mg of purified fusion protein. 
3. RESULTS AND DISCUSSION 
3.1. Characterization of the C7B2 antiserum 
kDa corresponding to GST-Cter-7B2. This fusion 
protein was purified in a single step by affinity chroma- 
tography (Fig. 1C). 
The plasmid pGEX-2T/Cter-7B2 used to produce The antiserum obtained from rabbits immunized with 
GST-Cter-7B2 in E. c&i is depicted in Fig. 1A. On the fusion protein attached 10 pg (20%) of radioactive 
Coomassie blue-stained SDS-PAGE gels, extracts from tracer under our RIA conditions (Fig. 2A,B). It was 
pGEX-2T-carrying bacteria incubated with IPTG specific for the 7B215h ,,, peptide and showed no cross- 
showed a prominent band of 27 kDa corresponding to reactivity to other synthetic peptides derived from the 
GST (Fig. 1B). Extracts from bacteria carrying pGEX- C-terminus of 7B2 (Fig. 2B), placing the recognized 
2T/Cter-7B2 contained an IPTG-induced protein of 31 epitope possibly between residues 156 and 165 of 
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Fig. 2. Characterization of the C7B2 antiserum. (A) Antiserum titration curve (initial dilution). (B) Antiserum binding of the tracer in the presence 
of increasing amounts of various synthetic peptides. 
pro7B2 (see Fig. 4C). ACTH, /?-endorphin and the 23- 
kDa 7B2 purified from porcine pituitary did not cross- 
react with this antiserum (data not shown). 
3.3. PutVfication cd sequencing qf’ Cter-7B2 
extracts only (Fig. 3B). Although the 23 kDa pituitary 
form of 7B2 also elutes at this time [lo], it is unlikely to 
be the immunoreactive material detected here as it is not 
recognized by the antiserum. We presume this late-elut- 
ing peak to be due to pro7B2. 
When the antiserum was used for RIA on HPLC To determine the nature of the immunoreactive 
fractions of culture media and extracts of VV:m7B2- protein eluting at 41 min, cells were incubated with 
infected AtT-20 cells, a large immunoreactivity peak [3SS]methionine, [‘Hlphenylalanine, [3H]leucine or 
was observed at 41 min with both samples (Fig. 3A,B). [3H]valine and materials recognized by antiserum were 
The Cter-7B2 peptide released by thrombin digestion of immunoprecipitated from the culture medium. 
GST-Cter-7B2 co-elutes with this peak. A smaller im- Radioactive immunoprecipitates were obtained with 
munoreactivity peak was detected at 57 min with the [3H]Phe, Val and Leu, but not with [“S]Met. Sequencing 
A MED!UM 
TIME (mm) 
CELL EXTRACT 
TIME (mln) 
Fig. 3. HPLC fractionation and RIA of 7B2 proteins. RIA results are expressed as percents of the highest level of immunoreactivity detected in 
the HPLC fractions of the culture medium. 
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Fig. 4. Sequencing of the C-terminal peptide. Edman degradation cycles of immunoprecipitatcs labelled with (A) [‘H]Val, and (B) with [jH]Leu. 
(C) Diagram showing potential proteolytic maturation sites (*) in pro7B2. Arrow indicates the deduced processing site. 
of the labelled material yielded [7H]Val peaks at cycles 
2, 14 and 15 (Fig. 4A), and [‘HJLeu peaks on cycles 1, 
6 and 11 (Fig. 4B). Except for the [3H]Leu peak on cycle 
1, the positions of all the radioactive peaks are pre- 
dictable for a peptide starting at residue 156 of mouse 
pro7B2 and generated by its processing after the string 
of basic residues Arg-Arg-Lys-Arg-ArgJ5’ Is5 (Fig. 4C). 
The source of [3H]Leu peak on cycle 1 has not been 
clarified. It may be due to non-specific adsorption of 
free Leu to the polybrene matrix of the sequenator, to 
contamination of the Cter-7B2 immunoprecipitates by 
another protein, or to a Ser-to-Leu mutation during 
virus propagation. Nonetheless, the absence of any 
other ambiguities in the deduced sequence indicates that 
the antiserum recognized the appropriate antigen rather 
selectively. Because the immunoprecipitate could be 
[“HI-labelled at the single Phe found in the C-terminal 
segment and because there is no additional processing 
site beyond this residue (see Fig. 4C), it is very likely 
that the peptide extends to the end of the pro7B2 se- 
quence and is 31 residues long. 
Taken together, these results confirm the precursor 
nature of 7B2. In pulse-chase studies with AtT-20 cells, 
we found that 7B2 was first produced as precursor of 
29 kDa which was rapidly converted to a 23 kDa form 
(Paquet et al., manuscript in preparation). This conver- 
sion apparently involves the release of the Cter-7B2 
peptide characterized above and could explain the lack 
of cross-reactivity between this antiserum and tissue- 
extracted 7B2. In a similar study with explants of 
Xenopus neurointermediate pituitary [ 1 I], the matura- 
tion site was tentatively placed at the Lys-Ly~‘~~-‘~~. The 
variation in processing site may reflect differences 
among tissues in resident proprotein convertases and in 
cellular environment [9]. 
This new antiserum should nicely complement the 
one against the amino terminal region [7] in studies of 
7B2 biosynthesis, maturation and secretion, as well as 
in the eventual definition of its biological role. 
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